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AbstrAct
Introduction Postoperative delirium (POD) is a common 
serious postoperative complication especially in older 
people and is associated with increased mortality, 
morbidity and healthcare costs. There is no clear 
consensus which anaesthesia is associated with less 
incidence of POD for older patients. We aim to assess 
whether regional anaesthesia results in lower incidence 
of POD comparing with general anaesthesia (GA) among 
older patients undergoing hip fracture surgery.
Methods and analysis RAGA-delirium is a pragmatic, 
multicentre, prospective, parallel grouped, randomised 
controlled clinical trial comparing RA or GA for hip fracture 
surgery. A total of 1000 patients who are 65 years or 
over and who are having planned hip fracture surgery in 
nine clinical trial centres of China will be randomised in 
a 1:1 ratio to receive either anaesthesia for the surgery. 
The primary endpoint will be the incidence of POD at 
day 7. The secondary endpoints will be the subtype, 
severity and duration of delirium, postoperative acute 
pain score, incidence of other postoperative non-delirium 
complications, quality of life and cost-effective outcomes. 
Randomisation will be performed at the patient level using 
computer-generated assignment. Outcome assessors will 
be blinded from intervention assignment. Assessments 
will be conducted before surgery, intraoperatively, 
postoperatively, during the hospital stay, at 30-day, 
6-month and 1-year postoperative intervals.
Potential impact of study This study will provide 
clinical evidence with a more robust methodology to 
help anaesthetists in selecting appropriate anaesthesia 
for older patients with high risk for POD. At the era of 
increasing emphasis on delirium prevention, this trial has 
the potential to inform the future national guideline to 
reduce POD.
Ethics and dissemination Ethical approved by the local 
institutional review board. Trial results will be presented 
at national and international academic conferences, and 
published in peer-reviewed journals.
trial registration number  ClinicalTrials. gov 
(NCT02213380); pre-results.
bAckground
Postoperative delirium (POD) is a common 
postoperative complication, especially in 
the elderly, and is associated with increased 
mortality, post-traumatic stress disorder, 
longer length of hospital stay, extra nursing 
requirements and increased healthcare cost. 
1 2 Systematic reviews have shown a high 
incidence of delirium in surgery after hip 
fracture (4%–53%).3 Currently there is no 
robust evidence demonstrating the efficacy 
of any specific treatment for POD, creating 
the urgent need for researches to investi-
gate delirium prevention. The aetiology of 
delirium remains poorly understood, but 
studies have highlighted some pre-existing 
and precipitating factors such as anaesthetic 
agents that may be associated with predispose 
to POD.4
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Protocol
strengths and limitations of this study
 ► This will be a randomised controlled trial with a 
more robust methodology to improve trial accuracy 
and decrease risk of potential bias.
 ► Methodology strengths of this trial include internet 
central randomisation, computer-generated 
assignment, blinded assessment and concealment 
allocation, and appropriate sample size estimation.
 ► The other strength is the pragmatic and multicentre 
design of nine study sites in order to depict the 
outcomes of anaesthesia methods in real-life routine 
clinical practice.
 ► The pragmatic and multicentre design may 
limit the consistency of interventions. However, 
this compromise of sample and measurement 
homogeneity is expected to be diluted with large 
sample size.
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Figure 1 Flow diagram of the RAGA trial. AE, adverse event; ASA, American Society of Anesthesiologists; CAM, Confusion 
Assessment Method; DRS-R-98, Delirium Rating Scale-Revised-98; MMSE, Mini-Mental State Examination; SAE, serious 
adverse event.
Anaesthesia may be classified into regional anaesthesia 
(RA) or general anaesthesia (GA). GA involves inducing 
sleep or loss of consciousness and is achieved by either 
inhalational agents or intravenous anaesthetic agents. 
RA involves an injection of local anaesthetic inside the 
spine (neuroaxial block) or around the nerves (periph-
eral nerve block) to prevent pain in the leg with the hip 
fracture. Older patients with hip fracture can be frail and 
often have many multiple medical comorbidities associ-
ated with advanced age5, which places them at high risk 
of morbidity and mortality after anaesthesia. There is 
no up-to-date prospective data4 and clear consensus as 
to whether which anaesthesia can lead to better patient 
outcomes undergoing a surgery. At present both RA and 
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GA are administered during surgery for elderly people. 
However, the eventual choice of anaesthetic regimen 
used is based on the preference and experience of the 
anaesthetist alongside discussion with the patient and 
their carers rather than evidence-based decision-making.6 
Recently, a Cochrane systematic review based on six studies 
including a total of 624 participants claimed no difference 
in the risk of acute confusional state was found between 
different anaesthetic regimens. However, current reviews 
were based on old and low-quality evidence, such as poor 
allocation concealment, assessor blinding or small sample 
sizes;7 thus any estimate of effect still remain uncertain.
Over the last 20 years, the elderly population is growing 
fast in most parts of the world8 9 and the number of 
older people undergoing surgical procedures has 
increased.10 11 Hip fractures are a global health problem, 
with over 1.6 million patients suffering hip fractures 
worldwide each year,12 13 of which 680 000 occur among 
the 70 million elderly people in China.14–17 50% of total 
global hip fractures will occur in Asia by the year 2050.18 
The majority of people with hip fracture are elderly 
and are treated surgically, which requires anaesthesia.19 
However, no studies have yet investigated the effect of RA 
and GA on the POD in elderly patients undergoing hip 
fracture surgery in China. The selection of an optimal 
anaesthesia regimen that can achieve the ideal anaes-
thetic effect during operation while reducing the influ-
ence on postoperative brain function in elderly patients 
is a challenge for anaesthetists and calls for a high-quality 
multicentre clinical trial.
MEthods And dEsIgn
study design
This is a pragmatic, multicentre, prospective, parallel 
grouped, randomised controlled clinical trial with cost-ef-
fective analysis. This follows the SPIRIT 2013 (Standard 
Protocol Items: Recommendations for Interventional 
Trials) statement.20 21 Figure 1 shows the design of the 
study.
objectives
Primary objective
The aim of the RAGA trial is to determine whether 
different types of anaesthesia (RA vs GA) given to older 
patients undergoing hip fracture surgery result in equiva-
lent incidence of POD.
Secondary objectives
 ► To compare the severity, type and duration of POD 
between the anaesthesia groups;
 ► To assess whether there are differences in incidence 
of POD in different patients (by age, dementia or 
delirious patients) between groups;
 ► To describe the frequency of analgesics, blood pres-
sure, pain in the postoperative period after either RA 
or GA and explore other possible factors associated 
with increased risk of POD;
 ► To compare the occurrence of non-delirium compli-
cations between the groups;
 ► To assess and compare cost-effectiveness of using RA 
or GA in terms of medical costs;
 ► To follow-up and analyse long-term outcomes and 
time to event data such as long-term cognitive dysfunc-
tion, quality of life and other mortality, and morbidity 
indices after POD during hospital stay and 12 months 
after hospital admission.
Participants
Study setting
This study will take place at nine hospitals in different 
regions of Mainland China. The hospitals have an annual 
total of 285 000 annual surgeries, of which 4580 were 
planned surgery for fragility hip fracture, with 2390 
patients over 65 years old per year.
The nine investigational centres are the following: Depart-
ment of Anaesthesiology, The Second Affiliated Hospital 
and Yuying Children’s Hospital of Wenzhou Medical 
University, Wenzhou, China; Department of Anaesthesi-
ology, Tongji Hospital, Tongji Medical college, Huazhong 
University of Science and Technology, Wuhan, China; 
Department of Anaesthesiology, The Central Hospital of 
Lishui City, Lishui, China; Department of Anaesthesiology, 
Lishui People’s Hospital, Lishui, China; Department of 
Anaesthesiology, The Second Hospital of Ningbo, Ningbo, 
China; Department of Anaesthesiology, The sixth Hospital 
of Ningbo, Ningbo, China; Department of Anaesthesi-
ology, The First Affiliated Hospital of Nanchang Univer-
sity, Nanchang, China; Department of Anaesthesiology, 
Taizhou Enze Hospital, Taizhou, China; Department of 
Anaesthesiology, The First Affiliated Hospital of Wenzhou 
Medical University, Wenzhou, China.
Study population
Inclusion criteria
 ► Patients ≥65 years old;
 ► Hospital admission for surgery for fragility hip frac-
ture (fragility hip fractures are defined as femoral 
neck, femoral head, intertrochanteric or the subtro-
chanteric fractures);
 ► American Society of Anesthesiologists class I–IV;
 ► The ability to receive written informed consent from 
the patient or patient’s legal representative.
Exclusion criteria
Patients presenting with one of the following criteria will 
not be included in the trial:
 ► Multiple trauma, multiple fractures or other fractures 
outside the inclusion criteria, such as pathological 
fractures, pelvic fractures, femur fractures;
 ► Contraindication for GA (drug allergies to GA or any 
other drugs administered during this trial);
 ► Contraindication for RA (infection at the site of 
needle insertion, coagulopathy, international normal-
ised ratio >1.4, platelet count <80×109/L, allergy to 
local anaesthetics);
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 ► Susceptibility to malignant hyperthermia;
 ► Current enrolment in a clinical trial of investigational 
medicine.
outcomes and measurements
Primary outcome
 ► The primary outcome is the incidence of POD during 
7 postoperative days, diagnosed with Confusion 
Assessment Method (CAM).22
Secondary outcomes
 ► The subtype, severity and duration of delirium in 7 
days after the surgery, diagnosed with the Delirium 
Rating Scale-Revised-98 (DRS-R-98)23 and CAM;
 ► Duration of delirium, measured by days from 
the onset of delirium symptom to resolution of 
symptoms;
 ► The intensity of postoperative pain, measured with 
acute pain score in 7 days after the surgery using 
Visual Analogue Scale (VAS)24;
 ► The occurrence of non-delirium in-hospital compli-
cations within 30 days after surgery, including chest 
infection, myocardial infarction, renal failure, gastro-
intestinal ileus;
 ► Length of hospital stay, measured by the sum of inpa-
tient days from admission to discharge;
 ► Mortality during hospital stay and during follow-up 
period after hospital admission;
 ► Incidence of delirium in clinic or at residence on 
30 day, 6 month, 12 month after surgery, diagnosed 
with CAM;
 ► Cognitive and functional decline on 30 day, 6 month, 
12 month after surgery, diagnosed with Mini-Mental 
State Examination (MMSE) and Hospital Anxiety and 
Depression Scale;
 ► Quality of life on 30 day, 6 month, 12 month after 
surgery, using 36-Item Short Form questionnaire;
 ► Economic parameters including total cost in hospital 
and expenditure for anaesthesia and resource using 
costs, including equipment and disposables required 
for each anaesthetic technique.
Assignment of interventions
Randomisation
Randomisation will be performed at the patient level. 
Consecutively screened and eligible patients will be 
included in the trial at each centre after initiation of the 
study. Patients will be allocated in a 1:1 ratio into either 
RA group or GA group 1 day before surgery using comput-
er-generated assignment (web or telephone developed by 
the study data management provider). Stratification will 
be performed to minimise group imbalances on these 
variables by the following factors: age (65–79, ≥80 years), 
presence of preoperative delirium (yes, no), periopera-
tive dementia (yes, no). The investigator or designee will 
complete a randomisation worksheet as detailed in the 
study manual.
Blinding
Owing to the nature of the study, it is not possible for 
the surgeon and anaesthetist delivering the interven-
tions to be blinded to the treatment options.25 In order 
to minimise any potential bias, investigators have been 
divided into two different teams: (1) Unblinded: the 
anaesthetist and other surgical staff who work in the 
operation theatre will know whether the participants 
have GA or RA. These staff will not be involved in the 
assessment of outcome measures. (2) Blinded: principal 
investigators (PIs), coinvestigators and statistician will 
not know patient’s group allocation. Data collectors or 
outcome assessors, for example, the medical staff who 
provide postoperative care in the ward and visit patients 
for preoperational assessment, hospital visits and subse-
quent follow-ups, will be blinded from group allocation 
throughout the study.
Implementation and data collection
Treatment and comparator
There will be two arms of research: RA group and GA 
group. Conducting of interventions will follow the 
national or local routine clinical practice in China. For 
an overview of the schedule see figure 1.
Due to the nature of a pragmatic trial with only a few 
exclusion criteria, no further efforts are proposed to 
strictly standardise the applied interventions. In both 
groups, patients will receive anaesthesia according to 
local practice. The type of medication, dosage and addi-
tional pain medication will be based on clinical proto-
cols of each study centre and be documented in detail 
in the medical record and in the Case Record Forms 
(CRFs). Experienced and qualified anaesthetists will be 
designated to perform the RA or GA. Prior to the study, 
study personnel are trained to follow the study protocol 
in accordance with the Good Clinical Practice (GCP) 
principles.
Recruitment and grouping
Patients will be recruited through the department of 
orthopaedics. All possible candidate patients for the trial 
will be provided with information sheets and informed 
about the aim of the trial, the treatment allocations, the 
workflow and the randomisation procedure. Written 
informed consent will be obtained from patients in the 
first instance. If the patient is assessed and deemed not 
have the capacity to provide written informed consent 
then their legally authorised representative and/or care-
givers will be approached to give agreement on behalf of 
the patient according to GCP.
During the screening visit (between 1 week and 1 day 
before operation), the inclusion and exclusion criteria 
will be assessed. If all criteria are fulfilled and informed 
consent is given, the patient will be included as candi-
dates. Trained members of the research team will enrol 
participants and implement the assignment of partici-
pants to either anaesthesia groups according to the centre 
randomisation the day before surgery. Group assignment 
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will be revealed to members of the anaesthetic team only 
when the patient enters the operating room.
Preanaesthetic assessment
After a patient has given informed consent, preanaes-
thetic assessment will be conducted including demo-
graphics, medical history, physical examination, cognitive 
status, comorbidities, current medication use and assess-
ment of preoperative quality of life. Then a specific form 
will be documented within 24 hours before surgery.
Data collectors will visit recruited patients from prean-
aesthetic assessment the day before surgery to 7 days after 
surgery, discharge and follow-up patients at 6 and 12 
months after the surgery to collect required data. Data 
collectors will receive specific training of using of CAM, 
DRS-R-98, MMSE and other tests used in this trial and will 
be blinded to the group allocation.
Premedication for anaesthesia will not be encouraged 
before surgery. Any medication impairing cognitive func-
tion will be avoided.
Anaesthesia procedure
GA group: For patients assigned to receive GA, anaesthesia 
will be induced with propofol (or etomidate), sufentanil 
(or fentanyl) and will be maintained with either intrave-
nous (propofol), inhalational (sevoflurane or isoflurane 
with or without nitrous oxide) through laryngeal mask 
airway, tracheal intubation, mechanical ventilation or 
combined intravenous–inhalational anaesthetics. Iliac 
fascia ‘3-in-1’, femoral nerve block or posterior lumbar 
plexus block, single nerve block or continuous nerve 
block are recommended blocking methods.
RA group: Regional anaesthetic techniques for the 
surgery include epidural anaesthesia, spinal anaesthesia 
and combined spinal and epidural, with or without addi-
tional peripheral nerve block according to anaesthetist 
experience. The type and dosage of local anaesthetic 
depend on anaesthetist experience as well. No sedative 
is administrated in RA group. Any medication impairing 
cognitive function, like midazolam or dexmedetomidine, 
will be avoided in both groups.
On the day of surgery, data collection will be performed 
and recorded with assessment of intraoperative and 
perioperative parameters as well as serious adverse 
events (SAEs). For perioperative information, data will 
be collected for duration and types of anaesthesia and 
surgery, doses of analgesics, sedatives and anaesthetic 
agents, intraoperative fluid balance, including blood or 
clotting products transfusion and postoperative anal-
gesic consumption and use of drugs with anticholinergic 
properties.
Postoperative observation and follow-up
Following surgery, patients will be sent to the postan-
aesthesia care unit (PACU) of each clinical centre for 
continuous routine vital signs monitoring, they will be 
discharged from PACU to the orthopaedic ward after they 
are assessed to have recovered from anaesthesia. Both 
groups will receive routine postoperative care on ortho-
paedic ward. Postoperative analgesia such as intravenous, 
epidural, nerve block analgesia and oral analgesics can be 
administered, according to the local procedures of each 
clinical trial site, aiming to maintain a VAS pain score 
≤30 mm, but any postoperative sedatives will be avoided.
During the postoperative visits, the primary and 
secondary endpoints, adverse events (AEs) and SAEs will 
be assessed and documented, including CAM, DRS-98-R 
(if applicable), VAS, analgesic use (if applicable), seda-
tive use (if applicable), postoperative morbidity and labo-
ratory results, such as serum haemoglobin, haematocrit, 
leucocytes, aspartate aminotransferase, alanine amino-
transferase, albumin, serum creatinine and urea concen-
trations, serum sodium and potassium and serum glucose 
concentration.
A daily delirium assessment will be performed for all 
randomised patients who will be followed up for 7 days 
after surgery or until discharge from the hospital. Over 
these 7 days, daily clinical assessments will be continued 
to evaluate duration of delirium until the symptoms of 
delirium are resolved or until the patient is discharged 
for patients who are delirious while daily assessments are 
discontinued for patients who are not delirious by day 7.
Adverse events or serious adverse event
An AE26 is described as any unpredictable or unfavour-
able clinical outcome associated with any medical inter-
ventions that occur during the study period. AE may be 
or may not be related to the study intervention. An SAE 
in the RAGA trial is defined as any unpredictable medical 
events that causes death, life threatening, results in signif-
icant incapacity/disability requires prolonged hospitalisa-
tion or is otherwise considered medically significant by 
the investigators.
In accordance with the guidance of GCP, AEs or SAEs 
will be reported using AE/SAE forms in patients Care 
Report Forms (CRF) including type, date, onset, severity, 
relation to intervention, management and outcome of 
these events. All AE/SAE will be monitored carefully, 
treated promptly if necessary based on clinical judgement 
and followed up until the events are properly resolved 
and patients are stabilised or recovered to normal.
Concomitant treatment
The medication concomitant with the RA or GA should 
be as simple as possible. Previous study reports that 
several drugs may increase the risk of POD.27–29 So the 
following medications such as intraoperative benzodi-
azepines are prohibited. Additionally, opioids (remifen-
tanil, sufentanil, fentanyl or morphine) and muscle 
relaxant (rocuronium, atracurium or cisatracurium) will 
be administered when deemed clinically necessary by 
the attending anaesthesiologists or physicians. Dosage, 
route, unit frequency of administration, and indication 
for administration and dates of all concomitant medica-
tion should be captured and recorded in details if used 
in clinical necessity.
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Study withdrawal
A patient will be withdrawn from the trial for any of the 
following reasons. The reason for the participant being 
withdrawn from the trial will be recorded on the ‘with-
drawal/change of status’ form:
1. Participants choose to withdraw consent;
2. If continuing, the trial is harmful to the patient’s 
well-being;
3. The participant becomes unable to complete the trial 
documentation and the trial investigators feel it is no 
longer appropriate for the participant to continue;
4. SAEs that are deemed related to the trial interven-
tions;
5. Safety reasons determined by the trial admission or 
the advisory board.
Data management
The data will be managed and analysed according to the 
guideline of GCP and handled in strictest confidence. All 
trial data will be recorded into an electronical case report 
form (eCRF) by investigator-designated and appropri-
ately trained personnel. The eCRF must be completed 
as soon as possible after the source document informa-
tion is collected. An explanation must be given for any 
missing data. A copy will be retained at the trial centre, 
and the original eCRF will be sent via web-based submit-
ting system to trial coordinating centre after accuracy and 
completeness checking by the data monitoring staff.
The completed CRF must be reviewed and input into 
a password protected trial database with double indepen-
dent entries. After checking for plausibility, consistency and 
completeness, the database will be exported into the Statis-
tical Analysis System (SAS). Appropriate backup copies of 
the database and related software files will be maintained. 
Databases are backed up by the database administrator in 
conjunction with any updates or changes to the database.
Data sharing statement
The data gathered will be anonymised for processing. 
Data will be held securely and used only by the researcher 
and supervisor. It will be held for a maximum of 3 years 
to inform the project and will then archived in an anony-
mised form and deposited.
All data generated during the project will be made 
freely available via the Research Data Repository of The 
Second Affiliated Hospital and Yuying Children’s Hospital 
of Wenzhou Medical University. DOIs to these data will 
be provided and cited in any published articles using 
the data and any other data generated in the project. No 
further security, licensing or ethical issues are related to the 
expected data. Any data relevant to a published article will 
be made available alongside the article when published.
statistics
Sample size estimation
The sample size calculation is based on incidence rate of 
POD. Previous published incidence of POD diagnosed 
using CAM ranged from 28% to 50% in the elderly 
patients (age 65) during hospital stay for hip fracture 
surgery. Observational studies in China estimated 3-day 
POD incidences of 11.1%–23.3%.30–32 Assuming that the 
7-day GA Group in the present study will have a similar 
average delirium incidence as in previous 3-day studies, 
we adopted a conservative estimation of 7-day postsurgery 
POD incidence undergoing GA of 26% and a reduction 
of 30% POD in group RA. Then 441 patients should be 
needed for each group to give power (1-β) of 0.80 and the 
significance level of 0.05 (two sided). Losses to follow-up 
for the primary outcome are estimated to be 10.0%. Thus, 
a total of 1000 patients will be recruited from the nine 
clinical trial centres in China.
Statistical analysis
Statistical analyses will be performed with SAS (SAS Insti-
tute) by the statistician team of the trial. Prior to the anal-
ysis of the final study data, a detailed Statistical Analysis 
Plan will be developed to describe all analyses that will 
be performed. Data will be primarily analysed according 
to the intention-to-treat (ITT) principle and additional 
evaluation per protocol will be compared with those of 
the ITT analysis.
All tests will be two sided and statistical significance will 
be considered at p<0.05. All parameters will be calculated 
and presented with estimates and 95% CIs. Differences 
between groups will be calculated. Primary outcome (the 
7-day incidence of POD) will be analysed using χ2 tests. 
Continuous secondary outcome measures, if normally 
distributed, will be tested using Student’s t-test, otherwise 
Mann-Whitney test will be employed. Categorical outcome 
variables will be tested with a χ2 test. The time-to-event 
data, such as delirium-free duration or discharge from 
hospital will be tested using a log-rank test. Safety and 
tolerability data will be summarised by treatment groups 
and will include the number of patients, the rate of occur-
rence, the severity and relationship to interventions.
Possible confounding factors include demography, 
fracture characteristics, type of surgery and perioperative 
and postoperative complications. Stratification will act as 
a fundamental adjustment method for controlling the 
most essential confounders. Subgroup analysis according 
to variables relevant to the risk of POD (age, existing 
cognitive impairment, preoperative delirium) will help 
to define the risks of POD. Baseline measurements of 
the outcome variables, together with factors such as age, 
gender, body mass index, comorbidities and patient pref-
erence, will be included as covariates. Model-adjusted 
ORs between the two treatment groups will be estimated 
and tested with logistic regression for adjusting baseline 
measures to compare differences between groups in the 
primary and in the secondary outcome measures.
Ethical and management considerations
The trial will be conducted in compliance with the 
protocol and GCP. Monitoring will be predefined in a 
study-specific monitoring manual, and will be conducted 
by Clinical Research Unit of The Second Affiliated 
Hospital and Yuying Children’s Hospital of Wenzhou 
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Medical University according to approved standard oper-
ating procedures. The monitor will verify the enrolment 
of patients, check the informed consent forms, verify the 
source data and entries into the CRF and regularly super-
vise the progress of the trial to assist the local investiga-
tors in conducting the study according to the protocol, 
as well as to meet regulatory and ethical requirements. 
In accordance with the standard operating procedures 
and policies of the local institutional review board (IRB)/
independent ethics committee, the site investigator will 
report SAEs to the PI and the IRB of the Second Affili-
ated Hospital and Yuying Children’s Hospital of Wenzhou 
Medical University.
Trial status
The current protocol is version 1.1. The randomised trial, 
which commenced in September 2014, is currently in the 
phase of participant enrolment and follow-up. To date 
(31 August 2016), 968 patients have been screened and 
399 patients have been randomised in this study. Recruit-
ment of patients is about 50% slower than expected, so 
the recruitment period of this trial will be extended from 
January 2016 to July 2018.
dIscussIon
The RAGA-delirium trial is to allow us to detect whether 
RA given to older patients undergoing hip fracture surgery 
is related to a significantly lower incidence of POD. Hip 
fracture will present a real social and economic chal-
lenge as the population ages and the number of fractures 
increases. Both RA and GA are widely used in hip frac-
ture surgery. Currently available evidence is controversial 
as to whether GA accelerates the cognitive impairment 
or whether RA reduces POD. A study examining elective 
surgery suggests no difference in POD when RA and GA 
are compared.33 However, the results require verification 
as the study was underpowered (n=29 per group).34 A 
recently published result of a clinical trial shows a contra-
dictive conclusion that the 30-day mortality was margin-
ally reduced for spinal anaesthesia 7/164 (4.3%) vs 5/158 
(3.2%) (p=0.57), while at 1 year it was lower for GA 20/163 
(12.1%) vs 32/158 (20.2%) (p=0.05). Methodological 
rigour in particular regarding randomisation allocation 
concealment and assessor blinding of these studies was 
suboptimal.5 The numbers of participants included are 
insufficient to eliminate a difference between the two 
techniques in the majority of outcomes studied. Large 
randomised trials reflecting actual clinical practice are 
required before drawing final conclusions.
strengths and limitations
In the present trial, a more robust methodology is 
adopted to decrease risk of potential bias. First, we are 
one of the few academic clinical research teams equipped 
with web-based central randomisation in China.
Usage of computer-generated assignment to assign 
randomisation to recruited patients to each group; 
additionally covariate adaptive randomisation is also 
possible using the method of minimisation to assess the 
imbalance of sample size among several covariates.
Clinical trials display greater difficulty instituting 
‘blinding’, we require data collectors and outcome asses-
sors to remain blinded to group allocation in order to 
prevent subsequent differential cointerventions or 
biased assessment of outcomes to minimise performance 
bias and a Hawthorne effect.23 These measures ensure 
grouping balance against bias in all the respects except 
the intervention each group received.35
Other strength is the pragmatic and multicentre design. 
We adopted a pragmatic design with the aim of depicting 
the outcomes of anaesthesia methods in real-life routine 
clinical practice which are more representable of clinical 
practice and producing results that can be generalised. 
Therefore, the anaesthesia methods for both groups will 
not be restricted to one or two specific methods in the 
trial.
On the other hand, however, the pragmatic and multi-
centre design may limit the accuracy of measurement of 
interventions and the plausibility of comparison. Unlike 
randomised clinical trial for medications, there is vari-
ation in interventions performed by anaesthetists in 
different centres due to the operational characteristics 
of anaesthesia. Furthermore, there is variability in the 
surgical interventions performed in various centres due 
to surgeon variability and numerous other variables. This 
compromise of sample and result homogeneity could 
introduce biases influencing both arms, but their effect 
will be diluted with large sample size.
conclusIon
In conclusion, this study will provide clinical evidence on 
the safety of RA and GA in older patients for hip fracture 
surgery. We propose to contribute to the emerging litera-
ture by developing a more robust pragmatic multicentre 
randomised controlled clinical trial. The results of the 
trial are expected to help anaesthetists in selecting appro-
priate anaesthesia in a specific subgroup of patients and 
especially those at high risk for POD.
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